PMID- 33790647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - High Expression of MDM2 and the p53 Protein is Predictive Biomarkers for Poor 
      Prognosis of Oesophageal Squamous Cell Carcinoma.
PG  - 2733-2744
LID - 10.2147/CMAR.S280326 [doi]
AB  - BACKGROUND AND OBJECTIVE: In the present study, we detected the expression of 
      MDM2 and p53 in oesophageal squamous cell carcinoma (OSCC) specimens, studied 
      their relationship with the survival of OSCC patients, and explored the potential 
      of MDM2 and p53 to serve as predictive OSCC tumour markers. PATIENTS AND METHODS: 
      Through immunohistochemistry and fluorescence in situ hybridization (FISH), we 
      detected the expression of MDM2 and the p53 protein in 157 OSCC specimens that 
      met the inclusion and exclusion criteria. After scoring the results, Pearson's 
      chi-square test and Cox regression were used for analysis. RESULTS: The results 
      showed that the rates of high MDM2 and p53 expression in OSCC tissues were 60.5% 
      and 51.0%, respectively. The expression levels of MDM2 and p53 in OSCC were 
      significantly positively correlated (p<0.001, r=0.414). In addition, the 
      pathological metastasis (M) status and MDM2 protein expression in OSCC were 
      significantly correlated (p=0.027), and high expression of the p53 protein was 
      positively correlated with OSCC transfer (p=0.005), pathological node status 
      (p=0.008), and clinical stage (p=0.003). Kaplan-Meier survival analysis showed 
      that the high expression of MDM2 and p53 was significantly related to the poor 
      prognosis of OSCC. Moreover, subgroup analysis of the TNM staging of OSCC 
      patients showed that the high expression of MDM2 and p53 was significantly 
      correlated with poor OS and DFS of OSCC patients in either stage I-II or III-IV 
      patients. Both univariate and Cox multivariate analyses showed that p53 and MDM2 
      can be used as independent factors for the prognosis of OSCC patients. Finally, 
      our FISH detection results for MDM2 showed that the high expression of MDM2 was 
      significantly correlated with the amplification of MDM2 (p=0.015). CONCLUSION: 
      This study shows that MDM2 and p53 can be used as independent predictors of the 
      prognosis of patients with oesophageal squamous cell carcinoma.
CI  - (c) 2021 Ye et al.
FAU - Ye, Juan
AU  - Ye J
AD  - Department of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi 
      Medical University, Zunyi, Guizhou, People's Republic of China.
AD  - Department of Experimental Research, Sun Yat-Sen University Cancer Center, State 
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Department of Experimental Research, Sun Yat-Sen University Cancer Center, State 
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, State 
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.
AD  - Department of Clinical Laboratory, Yunfu People's Hospital, Yunfu, Guangdong, 
      People's Republic of China.
FAU - Li, Zhongwen
AU  - Li Z
AD  - Department of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi 
      Medical University, Zunyi, Guizhou, People's Republic of China.
FAU - Lin, Runduan
AU  - Lin R
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, State 
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.
FAU - Song, Yiling
AU  - Song Y
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, State 
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.
FAU - Ni, Huanhe
AU  - Ni H
AD  - Department of Experimental Research, Sun Yat-Sen University Cancer Center, State 
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.
FAU - Gou, Xiaoxia
AU  - Gou X
AUID- ORCID: 0000-0002-3842-4007
AD  - Department of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi 
      Medical University, Zunyi, Guizhou, People's Republic of China.
FAU - Xie, Rongzhang
AU  - Xie R
AD  - Department of Clinical Laboratory, Yunfu People's Hospital, Yunfu, Guangdong, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210323
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8005260
OTO - NOTNLM
OT  - MDM2
OT  - biomarkers
OT  - oesophageal squamous cell carcinoma
OT  - p53
COIS- The authors declare no conflicts of interest in this work.
EDAT- 2021/04/02 06:00
MHDA- 2021/04/02 06:01
PMCR- 2021/03/23
CRDT- 2021/04/01 06:24
PHST- 2020/10/19 00:00 [received]
PHST- 2021/01/20 00:00 [accepted]
PHST- 2021/04/01 06:24 [entrez]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/04/02 06:01 [medline]
PHST- 2021/03/23 00:00 [pmc-release]
AID - 280326 [pii]
AID - 10.2147/CMAR.S280326 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Mar 23;13:2733-2744. doi: 10.2147/CMAR.S280326. 
      eCollection 2021.